High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma

Figure 5

CCK8 assay of Hep3B cells transfected with si-ANXA2P2 or negative control siRNA when treated with negative control, sorafenib (4 μmol/L, 8 μmol/L), regorafenib (5 μmol/L, 10 μmol/L), and lenvatinib (10 μmol/L, 20 μmol/L), respectively, for three days and measured at the time points of 24, 48, and 72 h. There was no significant difference in relative proliferation capability between the no-treatment group, negative control siRNA group, and si-ANXA2P2 group (a). The relative proliferation capability was not significantly different between the negative control siRNA group and the si-ANXA2P2 group when administered with sorafenib (b, c), regorafenib (d, e), and lenvatinib (f, g) with different concentrations at the time points of 24, 48, and 72 h.

(a)

(b)

(c)

(d)

(e)

(f)

(g)